MX2022007643A - Regimen de tratamiento del cancer una vez por dia con un inhibidor de prmt5. - Google Patents
Regimen de tratamiento del cancer una vez por dia con un inhibidor de prmt5.Info
- Publication number
- MX2022007643A MX2022007643A MX2022007643A MX2022007643A MX2022007643A MX 2022007643 A MX2022007643 A MX 2022007643A MX 2022007643 A MX2022007643 A MX 2022007643A MX 2022007643 A MX2022007643 A MX 2022007643A MX 2022007643 A MX2022007643 A MX 2022007643A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- once daily
- treatment regimen
- cancer treatment
- prmt5 inhibitor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 229940125897 PRMT5 inhibitor Drugs 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000011269 treatment regimen Methods 0.000 title 1
- 206010014733 Endometrial cancer Diseases 0.000 abstract 2
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 abstract 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 abstract 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 2
- HBGHQRGHFNTSDP-DJABAAGCSA-N (1S,2S,3S,5R)-3-[[6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl]oxy]-5-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol Chemical compound CC1=NC=NC2=C1C=CN2[C@@H]1C[C@H](OC2=C3CNCCC3=C(F)C(=C2)C(F)F)[C@@H](O)[C@H]1O HBGHQRGHFNTSDP-DJABAAGCSA-N 0.000 abstract 1
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 206010008342 Cervix carcinoma Diseases 0.000 abstract 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 abstract 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract 1
- 201000010881 cervical cancer Diseases 0.000 abstract 1
- 201000004101 esophageal cancer Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 206010044412 transitional cell carcinoma Diseases 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
- 208000023747 urothelial carcinoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Un método para tratar tipos de cáncer, que incluyen cáncer de páncreas, cáncer de endometrio, cáncer pulmonar de células no pequeñas (NSCLC), cáncer de endometrio, cáncer de cuello uterino, cáncer de vejiga, carcinoma de células escamosas de cabeza y cuello (HNSCC), carcinoma urotelial, cáncer de esófago y otros tipos de cáncer, en donde el método comprende la administración una vez por día, a un paciente que lo necesita, de una cantidad terapéuticamente eficaz de (1S,2S,3S,5R)-3-((6-(difluorometil)-5-f luoro-1,2,3,4-tetrahidroisoquinolin-8-il)oxi)-5-(4-metil-7H-pirro lo[2,3-d]pirimidin-7-il)ciclopentan-1,2-diol que tiene la estructura: (ver Fórmula), o una sal de este aceptable desde el punto de vista farmacéutico.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962949688P | 2019-12-18 | 2019-12-18 | |
| US202063066755P | 2020-08-17 | 2020-08-17 | |
| US202063108745P | 2020-11-02 | 2020-11-02 | |
| PCT/IB2020/061957 WO2021124096A1 (en) | 2019-12-18 | 2020-12-15 | Once daily cancer treatment regimen with a prmt5 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022007643A true MX2022007643A (es) | 2022-07-19 |
Family
ID=73856216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007643A MX2022007643A (es) | 2019-12-18 | 2020-12-15 | Regimen de tratamiento del cancer una vez por dia con un inhibidor de prmt5. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230043985A1 (es) |
| EP (1) | EP4076465B1 (es) |
| JP (1) | JP2021107381A (es) |
| KR (1) | KR20220101681A (es) |
| CN (1) | CN114845720A (es) |
| AU (1) | AU2020410418A1 (es) |
| BR (1) | BR112022009470A2 (es) |
| CA (1) | CA3164804A1 (es) |
| ES (1) | ES2969732T3 (es) |
| IL (1) | IL293351A (es) |
| MX (1) | MX2022007643A (es) |
| TW (1) | TW202128176A (es) |
| WO (1) | WO2021124096A1 (es) |
| ZA (1) | ZA202205794B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113908283A (zh) * | 2021-09-30 | 2022-01-11 | 上海交通大学医学院附属新华医院 | Prmt5抑制剂及其与pd-l1抗体阻断剂联合在治疗肺癌上的应用 |
| KR20240095421A (ko) * | 2021-10-06 | 2024-06-25 | 미라티 테라퓨틱스, 인크. | 암 치료를 위해 prmt5 억제제를 사용하는 병용 요법 |
| WO2024118943A2 (en) * | 2022-11-30 | 2024-06-06 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a prmt5 inhibitor |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| DK2242771T3 (da) | 2007-12-14 | 2013-08-26 | Pfizer | Bindingsmolekyler til den humane ox40-receptor |
| KR101527297B1 (ko) | 2010-09-09 | 2015-06-26 | 화이자 인코포레이티드 | 4-1ｂｂ 결합 분자 |
| SA112330278B1 (ar) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | مواد ضابطة جديدة وطرق للاستخدام |
| CA2852860C (en) | 2011-11-17 | 2020-06-09 | Matthew David DOROSKI | Cytotoxic peptides and antibody drug conjugates thereof |
| EP3164417A1 (en) | 2014-07-01 | 2017-05-10 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| RU2722381C2 (ru) | 2015-04-13 | 2020-05-29 | Пфайзер Инк. | Терапевтические антитела и их применения |
| CA2969295A1 (en) | 2016-06-06 | 2017-12-06 | Pfizer Inc. | Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor |
| WO2018222689A1 (en) | 2017-05-31 | 2018-12-06 | Stcube & Co., Inc. | Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof |
| AU2018275359C1 (en) | 2017-06-02 | 2022-02-03 | Pfizer Inc. | Antibodies specific for FLT3 and their uses |
| CA3127290A1 (en) * | 2019-01-23 | 2020-07-30 | Pfizer Inc. | Polymorph form of a monophosphate hydrate salt of a known tetrahydroisoquinoline derivative |
-
2020
- 2020-12-15 WO PCT/IB2020/061957 patent/WO2021124096A1/en not_active Application Discontinuation
- 2020-12-15 ES ES20828324T patent/ES2969732T3/es active Active
- 2020-12-15 EP EP20828324.2A patent/EP4076465B1/en active Active
- 2020-12-15 IL IL293351A patent/IL293351A/en unknown
- 2020-12-15 MX MX2022007643A patent/MX2022007643A/es unknown
- 2020-12-15 US US17/786,695 patent/US20230043985A1/en active Pending
- 2020-12-15 CN CN202080088180.7A patent/CN114845720A/zh active Pending
- 2020-12-15 CA CA3164804A patent/CA3164804A1/en active Pending
- 2020-12-15 AU AU2020410418A patent/AU2020410418A1/en not_active Abandoned
- 2020-12-15 KR KR1020227020255A patent/KR20220101681A/ko not_active Withdrawn
- 2020-12-15 BR BR112022009470A patent/BR112022009470A2/pt not_active Application Discontinuation
- 2020-12-15 TW TW109144273A patent/TW202128176A/zh unknown
- 2020-12-16 JP JP2020208183A patent/JP2021107381A/ja not_active Withdrawn
-
2022
- 2022-05-25 ZA ZA2022/05794A patent/ZA202205794B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022009470A2 (pt) | 2022-08-16 |
| JP2021107381A (ja) | 2021-07-29 |
| AU2020410418A1 (en) | 2022-06-09 |
| IL293351A (en) | 2022-07-01 |
| WO2021124096A1 (en) | 2021-06-24 |
| EP4076465A1 (en) | 2022-10-26 |
| ZA202205794B (en) | 2023-02-22 |
| CN114845720A (zh) | 2022-08-02 |
| ES2969732T3 (es) | 2024-05-22 |
| US20230043985A1 (en) | 2023-02-09 |
| TW202128176A (zh) | 2021-08-01 |
| KR20220101681A (ko) | 2022-07-19 |
| EP4076465C0 (en) | 2023-11-15 |
| CA3164804A1 (en) | 2021-06-24 |
| EP4076465B1 (en) | 2023-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022007643A (es) | Regimen de tratamiento del cancer una vez por dia con un inhibidor de prmt5. | |
| IL275379B2 (en) | Benzylamino-converted pyridopyrimidinones and novel antecedents as sos1 inhibitors | |
| MX2022015695A (es) | Medicina de camptotecina con alta unidad de conexion hidrofila y conjugado de la misma. | |
| PH12018502134A1 (en) | Methods of treating pediatric cancers | |
| WO2009099634A3 (en) | Picoplatin and amrubicin to treat lung cancer | |
| MY199967A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| MX2019013643A (es) | Terapia de combinacion de 7-bencil-10-(2-metilbencil)-2,6,7,8,9,10 -hexahidroimidazo[1,2-a]pirido [4,3-d]pirimidin-5(3h)-ona. | |
| IL299099B1 (en) | Combinations of cancer treatments | |
| MY169452A (en) | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts | |
| WO2011112953A3 (en) | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers | |
| TW201613589A (en) | Combination methods for treating cancers | |
| TN2014000194A1 (en) | Administration of nedd8-activating enzyme inhibitor and hypomethylating agent | |
| MX2018012457A (es) | Terapia combinatoria con inhibidores notch y cdk4/6. | |
| EP4218760A3 (en) | Treatment regimen utilizing neratinib for breast cancer | |
| MX2022009612A (es) | Combinacion de bi853520 con farmacos quimioterapeuticos. | |
| RU2018138626A (ru) | Комбинированная терапия ингибиторами notch и pi3k/mtor для применения в лечении рака | |
| NZ596861A (en) | Pyrrolidine-substituted flavones as radio-sensitizers for use in the treatment of cancer | |
| RU2017105817A (ru) | Комбинированная терапия | |
| WO2020096682A3 (en) | Use of tumor inflitrating lymphocytes for treating nsclc patients refractory for anti-pd-1 antibody | |
| MX2020011836A (es) | Actividad antitumoral in vitro y xenoinjerto de un xanteno halogenado contra tumores solidos pediatricos refractarios. | |
| MX2024006168A (es) | Composicion farmaceutica y uso de la misma. | |
| MX2022006155A (es) | Terapias anticancerosas con anamicina liposomica orientadas al pulmon. | |
| PH12021551951A1 (en) | Combination therapies for use in treating cancer | |
| AR120808A1 (es) | Régimen de tratamiento del cáncer una vez por día con un inhibidor de prmt5 | |
| UY39342A (es) | Tratamiento con poziotinib para el cáncer de pulmón de células no pequeñas |